Chongqing Claruvis Pharmaceutical Co., Ltd.

I期：主要目的：评价注射用重组A型肉毒毒素（YY001）治疗中、重度眉间纹的安全性和耐受性 次要目的：评价YY001治疗中、重度眉间纹的免疫原性。初步评价YY001治疗中、重度眉间纹的有效性。 II期：主要目的：评价注射用重组A型肉毒毒素（YY001）治疗中、重度眉间纹的有效性。评价YY001治疗中、重度眉间纹的安全性。 次要目的：评价YY001治疗中、重度眉间纹的其他有效性；评价YY001治疗中、重度眉间纹的其他安全性；评价YY001治疗中、重度眉间纹的免疫原性

This is a phase 1/2, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate safety,immunogenicity and efficacy of YY001 for the treatment of moderate to severe glabellar lines in male and female subjects of Chinese origin. The study has been designed to test the safety,efficacy,immunogenicity of YY001,and compare to onabotulinumtoxinA (BOTOX®) and placebo, in improving the appearance of moderate to severe glabellar lines.